With relapsed, platinum-resistant ovarian cancer, every clinical trial in history has just shown a 10-12 month median survival in this setting. However, background data (680 fresh surgical specimens) for the design of a clinical trial to determine the efficacy of assay-directed therapy of platinum-resistant ovarian cancer, submitted to the 2003 Society of Gynecologic Oncology meeting, had a 27 month median survival and a fair number of long-term survivors (2004-AB-171-SGO). All specimens were tested with two separate Medicare-approved cell culture assays (DISC and MTT) having cell-death endpoints.
American Journal of Obstetrics and Gynecology, 2003, 189, number 5: 1301-1307
Functional profiling with cell culture assays
http://cancerfocus.net/forum/showthread.php?t=253 " target="_blank" rel="nofollow">http://cancerfocus.net/forum/showthread.php?t=253
, 2003,
189, number 5: 1301-1307
Functional profiling with cell culture assays
http://cancerfocus.net/forum/showthread.php?t=253 " target="_blank" rel="nofollow">http://cancerfocus.net/forum/showthread.php?t=253